BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 32655578)

  • 1. Three Decades of Interferon-β in Multiple Sclerosis: Can We Repurpose This Information for the Management of SARS-CoV2 Infection?
    Severa M; Farina C; Salvetti M; Coccia EM
    Front Immunol; 2020; 11():1459. PubMed ID: 32655578
    [No Abstract]   [Full Text] [Related]  

  • 2. Interferon-β-1a Inhibition of Severe Acute Respiratory Syndrome-Coronavirus 2 In Vitro When Administered After Virus Infection.
    Clementi N; Ferrarese R; Criscuolo E; Diotti RA; Castelli M; Scagnolari C; Burioni R; Antonelli G; Clementi M; Mancini N
    J Infect Dis; 2020 Aug; 222(5):722-725. PubMed ID: 32559285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current Perspective of Antiviral Strategies against COVID-19.
    Ahidjo BA; Loe MWC; Ng YL; Mok CK; Chu JJH
    ACS Infect Dis; 2020 Jul; 6(7):1624-1634. PubMed ID: 32485102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune Modulation as a Therapeutic Option During the SARS-CoV-2 Outbreak: The Case for Antimalarial Aminoquinolines.
    Vitte J; Michel M; Mezouar S; Diallo AB; Boumaza A; Mege JL; Desnues B
    Front Immunol; 2020; 11():2159. PubMed ID: 32983179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Uncertainty about the Efficacy of Remdesivir on COVID-19.
    Yoo JH
    J Korean Med Sci; 2020 Jun; 35(23):e221. PubMed ID: 32537956
    [No Abstract]   [Full Text] [Related]  

  • 6. Oxytocin as a potential defence against Covid-19?
    Soumier A; Sirigu A
    Med Hypotheses; 2020 Jul; 140():109785. PubMed ID: 32344303
    [No Abstract]   [Full Text] [Related]  

  • 7. Drug repositioning is an alternative for the treatment of coronavirus COVID-19.
    Serafin MB; Bottega A; Foletto VS; da Rosa TF; Hörner A; Hörner R
    Int J Antimicrob Agents; 2020 Jun; 55(6):105969. PubMed ID: 32278811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Purposing Saikosaponins for the treatment of COVID-19.
    Bahbah EI; Negida A; Nabet MS
    Med Hypotheses; 2020 Jul; 140():109782. PubMed ID: 32353743
    [No Abstract]   [Full Text] [Related]  

  • 9. Therapeutic options for the treatment of 2019-novel coronavirus: An evidence-based approach.
    Sarma P; Prajapat M; Avti P; Kaur H; Kumar S; Medhi B
    Indian J Pharmacol; 2020; 52(1):1-5. PubMed ID: 32201439
    [No Abstract]   [Full Text] [Related]  

  • 10. Drug Repurposing Study Pinpoints Potential COVID-19 Antivirals.
    Abbasi J
    JAMA; 2020 Sep; 324(10):928. PubMed ID: 32897326
    [No Abstract]   [Full Text] [Related]  

  • 11. Rapid repurposing of drugs for COVID-19.
    Guy RK; DiPaola RS; Romanelli F; Dutch RE
    Science; 2020 May; 368(6493):829-830. PubMed ID: 32385101
    [No Abstract]   [Full Text] [Related]  

  • 12. Existing Drugs Might Treat COVID-19.
    Abbasi J
    JAMA; 2020 Jun; 323(22):2239. PubMed ID: 32515802
    [No Abstract]   [Full Text] [Related]  

  • 13. Lithium chloride combination with rapamycin for the treatment of COVID-19 pneumonia.
    Bou Khalil R
    Med Hypotheses; 2020 Sep; 142():109798. PubMed ID: 32413699
    [No Abstract]   [Full Text] [Related]  

  • 14. Immunomodulatory and Antiviral Activity of Metformin and Its Potential Implications in Treating Coronavirus Disease 2019 and Lung Injury.
    Chen X; Guo H; Qiu L; Zhang C; Deng Q; Leng Q
    Front Immunol; 2020; 11():2056. PubMed ID: 32973814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ribosomal proteins as a possible tool for blocking SARS-COV 2 virus replication for a potential prospective treatment.
    Rofeal M; El-Malek FA
    Med Hypotheses; 2020 Oct; 143():109904. PubMed ID: 32502901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Should we target the virus, the cell or the disease?].
    Nisole S; Saulnier A; Gatignol A
    Virologie (Montrouge); 2020 Jun; 24(3):135-141. PubMed ID: 32648548
    [No Abstract]   [Full Text] [Related]  

  • 17. Nutraceuticals have potential for boosting the type 1 interferon response to RNA viruses including influenza and coronavirus.
    McCarty MF; DiNicolantonio JJ
    Prog Cardiovasc Dis; 2020; 63(3):383-385. PubMed ID: 32061635
    [No Abstract]   [Full Text] [Related]  

  • 18. Quercetin and Vitamin C: An Experimental, Synergistic Therapy for the Prevention and Treatment of SARS-CoV-2 Related Disease (COVID-19).
    Colunga Biancatelli RML; Berrill M; Catravas JD; Marik PE
    Front Immunol; 2020; 11():1451. PubMed ID: 32636851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sofosbuvir for COVID-19 infection: A potential candidate.
    Gupta R; Dhamija P
    Indian J Pharmacol; 2020; 52(3):232-233. PubMed ID: 32874010
    [No Abstract]   [Full Text] [Related]  

  • 20. Imatinib is not a potent anti-SARS-CoV-2 drug.
    Zhao H; Mendenhall M; Deininger MW
    Leukemia; 2020 Nov; 34(11):3085-3087. PubMed ID: 32999432
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 20.